Abstract Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with
over 100 known substrates to deal with. How does GSK3 maintain control to selectively …

Abstract Glycogen synthase kinase‐3 (GSK3) is a highly evolutionarily conserved
serine/threonine protein kinase first identified as an enzyme that regulates glycogen …

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly
for hematologic malignancies. To date, however, genomic biomarkers to direct clinical …

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and
studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular …

Leukemia stem cells (LSCs) are thought to drive the genesis of acute myeloid leukemia
(AML) as well as relapse following chemotherapy. Because of their unique biology …

Over the past decade, rapid advances in genomics, proteomics and functional genomics
technologies that enable in-depth interrogation of cancer genomes and proteomes and high …

Cancer expression of PD-L1 suppresses anti-tumor immunity. PD-L1 has emerged as a
remarkable therapeutic target. However, the regulation of PD-L1 degradation is not …

Abstract Glycogen synthase kinase-3 (GSK-3) is well documented to participate in a
complex array of critical cellular processes. It was initially identified in rat skeletal muscle as …

Abstract Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that participates
in an array of critical cellular processes. GSK-3 was first characterized as an enzyme that …

Drugs targeting metabolism have formed the backbone of therapy for some cancers. We
sought to identify new such targets in acute myeloid leukemia (AML). The one-carbon folate …